AMODO-EO: A Practical Framework for Adaptive ObjectiveDiscovery in Multi-Objective Drug Optimization
Shetty, N. N.; Shetty, A.; Udupa, B. K.
Show abstract
Multi-objective optimization in drug discovery faces a fundamental limitation: the assumption that all relevant optimization criteria can be predefined. Traditional approaches using fixed objective sets often miss critical molecular trade-offs that emerge during the optimization process. We present AMODO-EO (Adaptive Multi-Objective Drug Optimization with Emergent Objectives), a novel framework that systematically discovers, validates, and integrates new optimization criteria during the search process by analyzing chemical data patterns. Building upon established automated feature engineering principles, AMODO-EO extends these techniques to dynamic multi-objective optimization contexts in drug discovery. The framework automatically generates candidate objectives from molecular descriptor relationships, validates them through rigorous statistical independence and variance criteria, and integrates them into the optimization process using adaptive weighting mechanisms. Comprehensive experiments on ChEMBL datasets demonstrate consistent identification of chemically meaningful objectives such as the hydrogen-bond acceptor/rotatable-bond ratio, which captures previously unspecified trade-offs between molecular polarity and flexibility. Statistical validation confirms that discovered objectives are independent of predefined criteria while providing significant discriminative power. Performance analysis shows that AMODO-EO successfully extends multi-objective formulations while maintaining competitive optimization performance on original objectives, with only 2-3% performance cost for the discovery capability. The framework opens new possibilities for adaptive optimization in chemical design by automatically revealing hidden molecular relationships that provide actionable insights for drug designers. Our approach represents a significant advancement in computational drug discovery by transforming multi-objective optimization from a purely exploitative process into one that systematically explores the space of potential optimization criteria.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AutoLead: An LLM-Guided Bayesian Optimization Framework for Multi-Objective Lead Optimization 96%
- Streamlining Computational Fragment-Based Drug Discovery through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening 96%
- Retro Drug Design: From Target Properties to Molecular Structures 95%
Similar papers in this journal
- Predicting kinase inhibitors using bioactivity matrix derived informer sets 95%
- Controlling astrocyte-mediated synaptic pruning signals for schizophrenia drug repurposing with Deep Graph Networks 94%
- Novel, provable algorithms for efficient ensemble-based computational protein design and their application to the redesign of the c-Raf-RBD:KRas protein-protein interface 93%
Similar papers in this journal
- Two-step multi-omics modelling of drug sensitivity in cancer cell lines to identify driving mechanisms 93%
- PharmaNet: Pharmaceutical discovery with deep recurrent neural networks. 93%
- Distinguishing classes of neuroactive drugs based on computational physicochemical properties and experimental phenotypic profiling in planarians 93%
Similar papers in this journal
- G-PLIP: Knowledge graph neural network for structure-free protein-ligand bioactivity prediction 93%
- Machine learning driven acceleration of biopharmaceutical formulation development using Excipient Prediction Software (ExPreSo) 93%
- Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.